PE20040600A1 - Derivados de triazol como antagonistas del receptor de taquicinina - Google Patents
Derivados de triazol como antagonistas del receptor de taquicininaInfo
- Publication number
- PE20040600A1 PE20040600A1 PE2003000400A PE2003000400A PE20040600A1 PE 20040600 A1 PE20040600 A1 PE 20040600A1 PE 2003000400 A PE2003000400 A PE 2003000400A PE 2003000400 A PE2003000400 A PE 2003000400A PE 20040600 A1 PE20040600 A1 PE 20040600A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- phenyl
- bisfluoromethylbenzyl
- methanone
- triazol
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 title 1
- -1 DIFLUOROMETHYL Chemical class 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 150000001335 aliphatic alkanes Chemical class 0.000 abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003254 radicals Chemical group 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA I DONDE D ES UN ALCANO (C1-C3)DIILO; R1 ES FENILO SUSTITUIDO POR HALO, ALQUILO C1-C4, ALCOXI C1-C4, CIANO, DIFLUOROMETILO, TRIFLUOROMETOXI; R4 ES UN RADICAL DE FORMULA Ia, Ib, ENTRE OTROS DONDE A1, A2, A3 Y A4 JUNTO AL C AL QUE ESTAN UNIDOS FORMAN UN ANILLO CARBOCICLICO O HETEROCICLICO AROMATICO EN EL QUE CADA UNO DE A1, A2, A3 Y A4 ES CR8 O N, DEBIENDO SER CR8 AL MENOS UNO DE A1, A2, A3 Y A4; G1, G2 Y G3 JUNTO AL C AL QUE ESTAN UNIDOS FORMAN UN ANILLO HETEROCICLICO AROMATICO EN EL QUE CADA UNO DE G1, G2 Y G3 ES CR8, N, OXIGENO O AZUFRE PUDIENDO SER O, S; R6 ES ALQUILO C1-C6, CICLOALQUILO C3-C6, FENILO ENTRE OTROS; X ES UN ENLACE ALCANO (C1-C3) DIILO, CH(OH), C(O), O, S(O)p, C=N-OR9, p ES 0, 1 O 2; R8 ES H, ALQUILO, HALO, ENTRE OTROS; R9 ES H, ALQUILO C1-C4 O BENCILO; R5 ES H, HALO, TRIFLUOROMETILO, ALQUILO C1-C4, CICLOALQUILO C3-C6, FURILO, TIENILO, PIRROLILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: {2-[1-(3,5-BISFLUOROMETILBENCIL)-5-PIRIDIN-4-IL-1H-[1,2,3]TRIAZOL-4-IL]PIRIDIN-3-IL]}-(2-CLOROFENIL)METANONA; {4-AMINO-2-[1-(3,5-BISFLUOROMETILBENCIL)-5-FENIL-1H-[1,2,3]TRIAZOL-4-IL]PIRIDIN-3-IL]}-(2-CLOROFENIL)METANONA; {5-AMINO-3-[1-(3,5-BISFLUOROMETILBENCIL)-5-FENIL-1H-[1,2,3]TRIAZOL-4-IL]PIRIDAZIN-4-IL}-(2-CLOROFENIL)METANONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON ANTAGONISTAS DEL RECEPTOR DE TAQUICININA Y SON UTILES PARA EL TRATAMIENTO DE LA ANSIEDAD
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37612102P | 2002-04-26 | 2002-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040600A1 true PE20040600A1 (es) | 2004-09-15 |
Family
ID=29270766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000400A PE20040600A1 (es) | 2002-04-26 | 2003-04-22 | Derivados de triazol como antagonistas del receptor de taquicinina |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7320994B2 (es) |
| EP (1) | EP1501809B1 (es) |
| JP (1) | JP4559087B2 (es) |
| KR (1) | KR100755577B1 (es) |
| CN (1) | CN1312136C (es) |
| AR (1) | AR039329A1 (es) |
| AT (1) | ATE384053T1 (es) |
| AU (1) | AU2003230829B8 (es) |
| BR (1) | BRPI0309534B8 (es) |
| CA (1) | CA2483159C (es) |
| CR (1) | CR7548A (es) |
| CY (1) | CY1107221T1 (es) |
| DE (1) | DE60318697T2 (es) |
| DK (1) | DK1501809T3 (es) |
| EA (1) | EA007720B1 (es) |
| EC (1) | ECSP045391A (es) |
| ES (1) | ES2298513T3 (es) |
| HR (1) | HRP20041008B1 (es) |
| IL (2) | IL164675A0 (es) |
| MX (1) | MXPA04010622A (es) |
| MY (1) | MY141559A (es) |
| NO (1) | NO333647B1 (es) |
| NZ (1) | NZ535886A (es) |
| PE (1) | PE20040600A1 (es) |
| PL (1) | PL212090B1 (es) |
| PT (1) | PT1501809E (es) |
| TW (1) | TWI265807B (es) |
| UA (1) | UA79113C2 (es) |
| WO (1) | WO2003091226A1 (es) |
| ZA (1) | ZA200408670B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| US20060160794A1 (en) * | 2003-06-12 | 2006-07-20 | Amegadzie Albert K | Tachykinin receptor antagonists |
| PT1675846E (pt) * | 2003-10-24 | 2010-04-20 | Lilly Co Eli | Novas formas cristalinas de {2-[1-(3,5-bis-trifluorometilbenzil)-5- iridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona |
| CA2581454A1 (en) | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
| WO2006083711A1 (en) * | 2005-02-01 | 2006-08-10 | Eli Lilly And Company | Tachykinin receptor antagonists |
| WO2006106711A1 (ja) | 2005-03-30 | 2006-10-12 | Eisai R & D Management Co., Ltd. | ピリジン誘導体を含有する抗真菌剤 |
| US8952176B2 (en) * | 2005-06-07 | 2015-02-10 | Shionogi & Co., Ltd. | Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity |
| KR100978961B1 (ko) * | 2005-07-25 | 2010-08-30 | 에프. 호프만-라 로슈 아게 | 치환된 트라이아졸 유도체 및 뉴로키닌 3 수용체길항물질로서의 상기 화합물의 용도 |
| TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| EP2233136A1 (en) * | 2006-08-18 | 2010-09-29 | Syngenta Limited | Use of HPPD Inhibitors in the Treatment of Depression and/or Withdrawal Symptoms Associated with Addictive Drugs |
| US8183264B2 (en) | 2006-09-21 | 2012-05-22 | Eisai R&D Managment Co., Ltd. | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same |
| MX2009006636A (es) | 2006-12-20 | 2009-06-30 | Lilly Co Eli | Nuevos intermediarios y procesos utiles en la rpeparacion de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]tr iazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona. |
| WO2009019278A1 (en) * | 2007-08-08 | 2009-02-12 | Neurosearch A/S | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| GB0722077D0 (en) | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| US20110086834A1 (en) * | 2008-06-26 | 2011-04-14 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| GB0823002D0 (en) * | 2008-12-17 | 2009-01-28 | Syngenta Participations Ag | Isoxazoles derivatives with plant growth regulating properties |
| DK2729147T3 (en) | 2011-07-04 | 2017-12-18 | Irbm - Science Park S P A | NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| ES2824552T3 (es) | 2015-03-04 | 2021-05-12 | Vanda Pharmaceuticals Inc | Método de tratamiento con tradipitant |
| US10287287B2 (en) | 2015-08-17 | 2019-05-14 | Eli Lilly And Company | Process development of a pyridine-containing NK-1 receptor antagonist |
| US11180484B2 (en) | 2016-05-31 | 2021-11-23 | Kalvista Pharmaceuticals Limited | Pyrazole derivatives as plasma kallikrein inhibitors |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| KR20200054232A (ko) | 2017-09-13 | 2020-05-19 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 |
| HUE071527T2 (hu) * | 2017-11-17 | 2025-09-28 | Vanda Pharmaceuticals Inc | Tradipitant gasztroparézis kezelésében történõ alkalmazásra |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| MX2020005168A (es) | 2017-11-29 | 2020-08-20 | Kalvista Pharmaceuticals Ltd | Formas de dosificacion que contienen un inhibidor calicreina de plasma. |
| EP4371613A3 (en) | 2018-02-26 | 2024-07-24 | Ospedale San Raffaele S.r.l. | Compounds for use in the treatment of ocular pain |
| WO2019236852A1 (en) | 2018-06-08 | 2019-12-12 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| KR20250140634A (ko) * | 2018-09-28 | 2025-09-25 | 반다 파마슈티칼즈, 인코퍼레이티드. | 멀미에서의 트라디피탄트의 용도 |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| EP3890735A1 (en) | 2018-12-03 | 2021-10-13 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| WO2020132513A1 (en) | 2018-12-21 | 2020-06-25 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
| WO2021173641A1 (en) | 2020-02-25 | 2021-09-02 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| US20230134843A1 (en) | 2020-03-11 | 2023-05-04 | Ospedale San Raffaele S.R.L. | Treatment of stem cell deficiency |
| JP2023520369A (ja) | 2020-03-26 | 2023-05-17 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによる下気道感染症の治療 |
| JP2023519570A (ja) | 2020-04-03 | 2023-05-11 | ネッレ セラピューティクス リミテッド | 新規使用 |
| CN113563306B (zh) * | 2020-04-28 | 2022-07-01 | 新发药业有限公司 | 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法 |
| BR112022024208A2 (pt) | 2020-06-02 | 2022-12-20 | Nerre Therapeutics Ltd | Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões |
| CN111662235B (zh) * | 2020-06-23 | 2023-12-22 | 黄淮学院 | 一种苯甲酰基哒嗪衍生物及其制备方法 |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| AU2023413130A1 (en) | 2022-12-21 | 2025-06-05 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
| CN116082253B (zh) * | 2023-02-25 | 2025-04-25 | 浙大城市学院 | 一种1-n-取代的1,2,3-三唑-4-甲酰胺衍生物及其制备方法 |
| WO2024223617A1 (en) * | 2023-04-24 | 2024-10-31 | Fundamental Pharma Gmbh | Effective means to modulate nmda receptor-mediated toxicity |
| US20250255855A1 (en) | 2024-02-09 | 2025-08-14 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL50699A0 (en) | 1975-10-28 | 1976-12-31 | Ici America Inc | Triazole derivatives |
| WO1995011880A1 (en) * | 1993-10-27 | 1995-05-04 | Merck Sharp & Dohme Limited | Substituted amides as tachykinin antagonists |
| US6175013B1 (en) | 1994-06-10 | 2001-01-16 | Eli Lilly And Company | Imidazolinyl tachykinin receptor antagonists |
| US5998444A (en) | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
| WO1997040025A1 (en) | 1996-04-19 | 1997-10-30 | Novo Nordisk A/S | Solid phase and combinatorial synthesis of substituted 1,2,3-triazoles and of arrays of substituted 1,2,3-triazoles |
| PT915880E (pt) | 1996-07-24 | 2007-12-31 | Bristol Myers Squibb Pharma Co | Azol triazinas e pirimidinas |
| US6060478A (en) * | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| WO1999007677A1 (en) | 1997-08-06 | 1999-02-18 | Eli Lilly And Company | 2-acylaminopropanamines as tachykinin receptor antagonists |
| ES2258485T3 (es) * | 1999-12-17 | 2006-09-01 | Schering Corporation | Antagonistas selectivos de neuroquinina. |
| TWI287003B (en) | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
| DE10036818A1 (de) * | 2000-07-28 | 2002-02-07 | Solvay Pharm Gmbh | Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten |
| JP2002123925A (ja) | 2000-10-13 | 2002-04-26 | Fuji Photo Film Co Ltd | 磁気記録媒体 |
| IL164787A0 (en) * | 2002-04-26 | 2005-12-18 | Lilly Co Eli | Tachykinin receptor antagonists |
-
2003
- 2003-04-22 US US10/512,249 patent/US7320994B2/en not_active Expired - Lifetime
- 2003-04-22 CN CNB038091046A patent/CN1312136C/zh not_active Expired - Lifetime
- 2003-04-22 DK DK03723929T patent/DK1501809T3/da active
- 2003-04-22 CA CA2483159A patent/CA2483159C/en not_active Expired - Lifetime
- 2003-04-22 PT PT03723929T patent/PT1501809E/pt unknown
- 2003-04-22 KR KR1020047017206A patent/KR100755577B1/ko not_active Expired - Lifetime
- 2003-04-22 HR HRP20041008AA patent/HRP20041008B1/hr not_active IP Right Cessation
- 2003-04-22 EP EP03723929A patent/EP1501809B1/en not_active Expired - Lifetime
- 2003-04-22 AT AT03723929T patent/ATE384053T1/de active
- 2003-04-22 EA EA200401431A patent/EA007720B1/ru not_active IP Right Cessation
- 2003-04-22 WO PCT/US2003/010681 patent/WO2003091226A1/en not_active Ceased
- 2003-04-22 MX MXPA04010622A patent/MXPA04010622A/es active IP Right Grant
- 2003-04-22 TW TW092109375A patent/TWI265807B/zh not_active IP Right Cessation
- 2003-04-22 PL PL373504A patent/PL212090B1/pl unknown
- 2003-04-22 UA UA20041008646A patent/UA79113C2/uk unknown
- 2003-04-22 AR ARP030101377A patent/AR039329A1/es unknown
- 2003-04-22 DE DE60318697T patent/DE60318697T2/de not_active Expired - Lifetime
- 2003-04-22 BR BRPI0309534A patent/BRPI0309534B8/pt not_active IP Right Cessation
- 2003-04-22 AU AU2003230829A patent/AU2003230829B8/en not_active Expired
- 2003-04-22 ES ES03723929T patent/ES2298513T3/es not_active Expired - Lifetime
- 2003-04-22 PE PE2003000400A patent/PE20040600A1/es not_active Application Discontinuation
- 2003-04-22 NZ NZ535886A patent/NZ535886A/en not_active IP Right Cessation
- 2003-04-22 JP JP2003587786A patent/JP4559087B2/ja not_active Expired - Lifetime
- 2003-04-22 MY MYPI20031515A patent/MY141559A/en unknown
-
2004
- 2004-10-18 IL IL16467504A patent/IL164675A0/xx not_active IP Right Cessation
- 2004-10-25 CR CR7548A patent/CR7548A/es unknown
- 2004-10-26 EC EC2004005391A patent/ECSP045391A/es unknown
- 2004-10-26 ZA ZA200408670A patent/ZA200408670B/xx unknown
- 2004-11-24 NO NO20045120A patent/NO333647B1/no not_active IP Right Cessation
-
2008
- 2008-02-28 CY CY20081100235T patent/CY1107221T1/el unknown
-
2009
- 2009-04-07 IL IL198122A patent/IL198122A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040600A1 (es) | Derivados de triazol como antagonistas del receptor de taquicinina | |
| RU2386622C2 (ru) | Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы | |
| AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
| ES2682282T3 (es) | Compuestos bicíclicos sustituidos con sulfonilo como moduladores de PPAR | |
| NO20060219L (no) | Forbindelser | |
| PE59999A1 (es) | Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona-8-sustituidos | |
| NO20063380L (no) | Triazolderivater som vasopressinantagonister | |
| PE20050525A1 (es) | Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1 | |
| CA2532818A1 (en) | (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists | |
| CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20050265A1 (es) | Derivados de acido alquilarilo como inhibidores de diacilglicerol aciltransferasa tipo 1 (dgat-1) | |
| PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
| MX9203249A (es) | Derivados del acido bencimidazolin-2-oxo-1-carboxilico y composiciones farmaceuticas que los contienen. | |
| AR061486A1 (es) | Derivados de 2-pirazinacarboxamida | |
| NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| AR022019A1 (es) | Un compuesto de imidazol y las composiciones farmaceuticas que lo contienen | |
| PE20081504A1 (es) | Compuestos de biciclocarboxiamida sustituidos | |
| PE20081850A1 (es) | Derivados ciclizados como inhibidores de la eg-5 | |
| PE20080843A1 (es) | Inhibidores de renina y metodo para su utilizacion | |
| PL361361A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| NO883487L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser. | |
| DE602006011752D1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
| AR045791A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
| AR057296A1 (es) | Diarilsulfona sulfonamidas y el uso de las mismas | |
| PT1210320E (pt) | Aminobenzofenonas como inibidores de il-1beta e tnf-alfa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |